Zobrazeno 1 - 10
of 22
pro vyhledávání: '"R W Whitcomb"'
Publikováno v:
Diabetes Care. 21:1455-1461
OBJECTIVE To determine the ability of troglitazone to reduce requirements for injected insulin while maintaining blood glucose levels in insulin-treated patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This 26-week double-blind study with o
Publikováno v:
Diabetes Care. 21:1462-1469
OBJECTIVE To determine if the combination of troglitazone (a peroxisome proliferator-activated receptor-γ activator) and sulfonylurea will provide efficacy not attainable by either medication alone. RESEARCH DESIGN AND METHODS There were 552 patient
Autor:
M. N. Ghazzi, J. E. Perez, T. K. Antonucci, J. H. Driscoll, S. M. Huang, B. W. Faja, R. W. Whitcomb
Publikováno v:
Diabetes. 46:433-439
Publikováno v:
Diabetes. 46:433-439
Troglitazone is a thiazolidinedione under development for the treatment of NIDDM and potentially other insulin-resistant disease states. Treatment with troglitazone is associated with an improvement in hyperglycemia, hyperinsulinemia, and insulin-med
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 73:621-628
Although prior studies have suggested that estrogens exert their negative feedback effect at the pituitary level in men, these conclusions have been based on models that evaluate changes in LH pulse amplitude and frequency and, therefore, only provid
Publikováno v:
Clinical Chemistry. 36:340-344
Measurement of the urinary excretion of lutropin (LH) and follitropin (FSH) and their common free alpha subunit (FAS) assists in monitoring the maturation of the hypothalamic-pituitary-gonadal axis and in understanding the physiology of the pituitary
Autor:
R, Azziz, D, Ehrmann, R S, Legro, R W, Whitcomb, R, Hanley, A G, Fereshetian, M, O'Keefe, M N, Ghazzi
Publikováno v:
The Journal of clinical endocrinology and metabolism. 86(4)
We hypothesized that the administration of troglitazone, an insulin-sensitizing agent of the thiazolidinedione class, would improve the ovulatory dysfunction, hirsutism, hyperandrogenemia, and hyperinsulinemia of polycystic ovary syndrome (PCOS) pati
Publikováno v:
The Journal of clinical endocrinology and metabolism. 83(9)
To assess the effects of troglitazone monotherapy on glycemic control in patients with type 2 diabetes mellitus, we carried out a 6-month, randomized, double-blind, placebo-controlled study in 24 hospital and outpatient clinics in the United States a
Publikováno v:
Diabetes care. 21(9)
To determine the ability of troglitazone to reduce requirements for injected insulin while maintaining blood glucose levels in insulin-treated patients with type 2 diabetes.This 26-week double-blind study with open-label extension included patients w
Publikováno v:
Diabetes. 46(3)
Troglitazone is a thiazolidinedione under development for the treatment of NIDDM and potentially other insulin-resistant disease states. Treatment with troglitazone is associated with an improvement in hyperglycemia, hyperinsulinemia, and insulin-med